Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Ethypharm-Mesalazine

More Like This

Dr. Aron Blaesi, inventor of expandable, gastroretentive fibrous dosage forms presenting dosage forms before and after expansion due to water absorption. (Photo: Business Wire)

Enzian Pharmaceutics Develops a Novel Dosage Form for Enhanced Efficacy and Reduced Side Effects of Cancer Therapies

e-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH

PR Newswire associated0

ACQUISITION OF ARGATROBAN BUSINESS IN EUROPE

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

Enteralia Bioscience SRL Acquires TFarma SRL

PR Newswire associated0

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

Samsung Bioepis office in Songdo, Incheon, Republic of Korea

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

PR Newswire associated0

ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence